133 related articles for article (PubMed ID: 21287607)
1. Kinetics, in silico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: the role of water molecules examined.
Hayes JM; Skamnaki VT; Archontis G; Lamprakis C; Sarrou J; Bischler N; Skaltsounis AL; Zographos SE; Oikonomakos NG
Proteins; 2011 Mar; 79(3):703-19. PubMed ID: 21287607
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
4. Multiple allosteric sites on muscarinic receptors.
Birdsall NJ; Lazareno S; Popham A; Saldanha J
Life Sci; 2001 Apr; 68(22-23):2517-24. PubMed ID: 11392621
[TBL] [Abstract][Full Text] [Related]
5. K252a is a potent and selective inhibitor of phosphorylase kinase.
Elliott LH; Wilkinson SE; Sedgwick AD; Hill CH; Lawton G; Davis PD; Nixon JS
Biochem Biophys Res Commun; 1990 Aug; 171(1):148-54. PubMed ID: 2393389
[TBL] [Abstract][Full Text] [Related]
6. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
Alexacou KM; Hayes JM; Tiraidis C; Zographos SE; Leonidas DD; Chrysina ED; Archontis G; Oikonomakos NG; Paul JV; Varghese B; Loganathan D
Proteins; 2008 May; 71(3):1307-23. PubMed ID: 18041758
[TBL] [Abstract][Full Text] [Related]
7. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.
Muñoz C; Adasme F; Alzate-Morales JH; Vergara-Jaque A; Kniess T; Caballero J
J Mol Graph Model; 2012 Feb; 32():39-48. PubMed ID: 22070999
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics approach to probe PKCβII-ligand interactions and influence of crystal water molecules on these interactions.
Grewal BK; Bhat J; Sobhia ME
Expert Opin Ther Targets; 2015 Jan; 19(1):13-23. PubMed ID: 25363346
[TBL] [Abstract][Full Text] [Related]
9. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine.
Lamers MB; Antson AA; Hubbard RE; Scott RK; Williams DH
J Mol Biol; 1999 Jan; 285(2):713-25. PubMed ID: 9878439
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
11. Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor.
Nisha CM; Kumar A; Vimal A; Bai BM; Pal D; Kumar A
J Mol Graph Model; 2016 Apr; 65():100-7. PubMed ID: 26967552
[TBL] [Abstract][Full Text] [Related]
12. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
Shen M; Zhou S; Li Y; Li D; Hou T
Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
[TBL] [Abstract][Full Text] [Related]
13. Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex.
Kosmopoulou MN; Leonidas DD; Chrysina ED; Bischler N; Eisenbrand G; Sakarellos CE; Pauptit R; Oikonomakos NG
Eur J Biochem; 2004 Jun; 271(11):2280-90. PubMed ID: 15153119
[TBL] [Abstract][Full Text] [Related]
14. Caspase-3 dependent cleavage and activation of skeletal muscle phosphorylase b kinase.
Hilder TL; Carlson GM; Haystead TA; Krebs EG; Graves LM
Mol Cell Biochem; 2005 Jul; 275(1-2):233-42. PubMed ID: 16335803
[TBL] [Abstract][Full Text] [Related]
15. Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Mashkani B; Griffith R; Ashman LK
Bioorg Med Chem; 2010 Mar; 18(5):1789-97. PubMed ID: 20156689
[TBL] [Abstract][Full Text] [Related]
16. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.
Vankayalapati H; Bearss DJ; Saldanha JW; Muñoz RM; Rojanala S; Von Hoff DD; Mahadevan D
Mol Cancer Ther; 2003 Mar; 2(3):283-94. PubMed ID: 12657723
[TBL] [Abstract][Full Text] [Related]
17. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.
Tsirkone VG; Tsoukala E; Lamprakis C; Manta S; Hayes JM; Skamnaki VT; Drakou C; Zographos SE; Komiotis D; Leonidas DD
Bioorg Med Chem; 2010 May; 18(10):3413-25. PubMed ID: 20430629
[TBL] [Abstract][Full Text] [Related]
18. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
Tsitsanou KE; Hayes JM; Keramioti M; Mamais M; Oikonomakos NG; Kato A; Leonidas DD; Zographos SE
Food Chem Toxicol; 2013 Nov; 61():14-27. PubMed ID: 23279842
[TBL] [Abstract][Full Text] [Related]
19. Oxime-dipeptides as anticholinesterase, reactivator of phosphonylated-serine of AChE catalytic triad: probing the mechanistic insight by MM-GBSA, dynamics simulations and DFT analysis.
Chadha N; Tiwari AK; Kumar V; Lal S; Milton MD; Mishra AK
J Biomol Struct Dyn; 2015; 33(5):978-90. PubMed ID: 24805972
[TBL] [Abstract][Full Text] [Related]
20. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
Schulze-Gahmen U; De Bondt HL; Kim SH
J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
